NZ745023A - Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses - Google Patents

Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses

Info

Publication number
NZ745023A
NZ745023A NZ745023A NZ74502317A NZ745023A NZ 745023 A NZ745023 A NZ 745023A NZ 745023 A NZ745023 A NZ 745023A NZ 74502317 A NZ74502317 A NZ 74502317A NZ 745023 A NZ745023 A NZ 745023A
Authority
NZ
New Zealand
Prior art keywords
trifluoroacetate salt
crystalline form
tlr7 agonist
preparation methods
methods
Prior art date
Application number
NZ745023A
Other languages
English (en)
Inventor
Zhaozhong Ding
Ling Yang
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of NZ745023A publication Critical patent/NZ745023A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
NZ745023A 2016-02-05 2017-02-04 Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses NZ745023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
PCT/CN2017/072894 WO2017133687A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Publications (1)

Publication Number Publication Date
NZ745023A true NZ745023A (en) 2022-09-30

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ745023A NZ745023A (en) 2016-02-05 2017-02-04 Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN112105620B (zh) * 2018-05-25 2026-02-24 正大天晴药业集团股份有限公司 用于治疗肺癌的tlr7激动剂及其药物组合
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
JP5813785B2 (ja) 2011-02-04 2015-11-17 デュケイン ユニバーシティー オブ ザ ホリー スピリット 抗チューブリン活性を有する二環式および三環式のピリミジンチロシンキナーゼ阻害剤ならびに患者の処置方法
WO2013103967A1 (en) 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
MX386924B (es) * 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
JP6216387B2 (ja) * 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 新規化合物
WO2015168269A1 (en) * 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
SG11201608299TA (en) * 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CN112898308B (zh) 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
MY198137A (en) 2023-08-07
HK1259182A1 (zh) 2019-11-29
EP3412674B1 (en) 2020-09-16
EP3412674A1 (en) 2018-12-12
EP3412674A4 (en) 2019-07-17
BR112018015878A2 (pt) 2018-12-26
SG11201806688QA (en) 2018-09-27
CA3013521A1 (en) 2017-08-10
AU2017214135A1 (en) 2018-08-23
UA121276C2 (uk) 2020-04-27
HUE052210T2 (hu) 2021-04-28
CN108602833A (zh) 2018-09-28
AR107550A1 (es) 2018-05-09
TWI778952B (zh) 2022-10-01
PH12018501641B1 (en) 2021-03-26
IL260981B (en) 2022-05-01
TW201728591A (zh) 2017-08-16
MX2018009503A (es) 2018-12-11
US10683296B2 (en) 2020-06-16
KR102393281B1 (ko) 2022-05-02
CN107043377A (zh) 2017-08-15
ZA201805240B (en) 2024-09-25
ES2834304T3 (es) 2021-06-17
AU2017214135B2 (en) 2020-08-13
CA3013521C (en) 2022-07-12
WO2017133687A1 (zh) 2017-08-10
PH12018501641A1 (en) 2019-06-03
US20190031666A1 (en) 2019-01-31
DK3412674T3 (da) 2020-11-09
CL2018002101A1 (es) 2018-12-07
KR20180104118A (ko) 2018-09-19
JP6877450B2 (ja) 2021-05-26
MX374300B (es) 2025-03-06
CN108602833B (zh) 2020-07-28
JP2019504103A (ja) 2019-02-14
EA201891772A1 (ru) 2019-01-31
EA037048B1 (ru) 2021-01-29

Similar Documents

Publication Publication Date Title
NZ744884A (en) Tlr7 agonist crystalline form a, preparation method and use thereof
ZA201805240B (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
NZ747259A (en) Soluble c5ar antagonists
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
TN2018000219A1 (en) Soluble guanylate cyclase stimulators
NZ630800A (en) Methods of preparing substituted nucleotide analogs
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
MX2018009502A (es) Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios.
MY191352A (en) Aldosterone synthase inhibitors
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
MX372682B (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
MX2017001408A (es) Derivados de serina como agonistas del receptor de grelina.
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
WO2015102017A8 (en) Processes for the preparation of lorcaserin
IL265013B (en) Process for the preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[3,2-b;3',4'-d]pyrrole
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
IN2013CH05870A (enExample)
UA80534U (uk) 1-[[3-(4,7-ДИГІДРО-1-МЕТИЛ-7-ОКСО-3-ПРОПІЛ-1Н-ПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ІЛ)-4-ЕТОКСИФЕНІЛ]СУЛЬФОНІЛ]-4-МЕТИЛПІПЕРАЗИН ТА ЙОГО ФАРМАЦЕВТИЧНО ПРИЙНЯТНІ СОЛІ

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2025 BY CPA GLOBAL

Effective date: 20231221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251218